Intrinsic apoptosis circumvents the functional decline of circulating platelets but does not cause the storage lesion

Blood

Volumn 132, Issue 2, 2018, Pages 197-209

  Pleines, Irina ^a,b,c   Lebois, Marion ^a   Gangatirkar, Pradnya ^a   Au, Amanda E ^a,b   Lane, Rachael M ^a,d   Henley, Katya J ^a   Kauppi, Maria ^a,b   Corbin, Jason ^a   Cannon, Ping ^a   Bernardini, Jonathan ^a,b   Alwis, Imala ^e,f   Jarman, Kate E ^a,b   Ellis, Sarah ^b,g   Metcalf, Donald ^a   Jackson, Shaun P ^e,f,h   Schoenwaelder, Simone M ^e,f   Kile, Benjamin T ^a,b,d   Josefsson, Emma C ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d MONASH UNIVERSITY   (Australia)

^e HEART RESEARCH INSTITUTE   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROCOAGULANT; PROTEIN BAK; PROTEIN BAX; BIOLOGICAL MARKER; CASPASE; PROTEIN BCL X;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLEEDING TIME; CELL DAMAGE; CELL GRANULE; CELL VIABILITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STORAGE TEMPERATURE; THROMBOCYTE; THROMBOCYTE PRESERVATION; THROMBUS; ANIMAL; BLOOD CELL COUNT; BLOOD CLOTTING; CELL SURVIVAL; DISEASE PREDISPOSITION; GENETICS; GENOTYPE; KNOCKOUT MOUSE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BIOMARKERS; BLEEDING TIME; BLOOD CELL COUNT; BLOOD COAGULATION; BLOOD PLATELETS; CASPASES; CELL SURVIVAL; DISEASE SUSCEPTIBILITY; FEMALE; GENOTYPE; MALE; MICE; MICE, KNOCKOUT; MITOCHONDRIA; SIGNAL TRANSDUCTION;

EID: 85050599622     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-11-816355     Document Type: Article

References (62)

1. Franco RS. Measurement of red cell lifespan and aging. Transfus Med Hemother. 2012; 39(5):302-307.
2. Leeksma CH, Cohen JA. Determination of the life of human blood platelets using labelled diisopropylfluorophosphanate. Nature. 1955; 175(4456):552-553.
3. Aster RH, Jandl JH. Platelet sequestration in man. II. Immunological and clinical studies. J Clin invest. 1964;43(5):856-869.
4. Murphy S, Gardner FH. Effect of storage temperature on maintenance of platelet viability–deleterious effect of refrigerated storage. N Engl J Med. 1969;280(20):1094-1098.
5. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell. 2003;112(1):87-97.
6. Rumjantseva V, Grewal PK, Wandall HH, et al. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med. 2009; 15(11):1273-1280.
7. Murphy S, Sayar SN, Gardner FH. Storage of platelet concentrates at 22 degrees C. Blood. 1970;35(4):549-557.
8. Thiagarajan P, Afshar-Kharghan V. Platelet transfusion therapy. Hematol Oncol Clin North Am. 2013;27(3):629-643.
9. McArthur K, Chappaz S, Kile BT. Apoptosis in megakaryocytes and platelets: the life and death of a lineage. Blood. 2018;131(6): 605-610.
10. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47-59.
11. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6): 1173-1186.
12. Josefsson EC, James C, Henley KJ, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med. 2011;208(10):2017-2031.
13. Kodama T, Takehara T, Hikita H, et al. Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology. 2010;138(7):2487-2498.
14. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943-951.
15. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2): 202-208
16. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311-322.
17. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9): 3421-3428.
18. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29(7):909-916.
19. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488-496.
20. Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010; 11(12):1149-1159.
21. Kodama T, Takehara T, Hikita H, et al. BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem. 2011;286(16):13905-13913.
22. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 2009;114(3):663-666.
23. Vandenberg CJ, Josefsson EC, Campbell KJ, et al. Loss of Bak enhances lymphocytosis but does not ameliorate thrombocytopaenia in BCL-2 transgenic mice. Cell Death Differ. 2014;21(5):676-684.
24. Detwiler TC, Odell TT Jr, MacDONALD TP. Platelet size, ATP content, and clot retraction in relation to platelet age. Am J Physiol. 1962; 203:107-110.
25. Hirsh J, Glynn MF, Mustard JF. The effect of platelet age on platelet adherence to collagen. J Clin Invest. 1968;47(3):466-473.
26. Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest. 1969; 48(6):1083-1087.
27. Blajchman MA, Senyi AF, Hirsh J, Genton E, George JN. Hemostatic function, survival, and membrane glycoprotein changes in young versus old rabbit platelets. J Clin Invest. 1981; 68(5):1289-1294.
28. Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118(6):1663-1674.
29. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148(7):2207-2216.
30. White MJ, Schoenwaelder SM, Josefsson EC, et al. Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood. 2012;119(18):4283-4290.
31. Bevers EM, Comfurius P, van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem. 1982;122(2): 429-436.
32. Zwaal RF, Comfurius P, van Deenen LL. Membrane asymmetry and blood coagulation. Nature. 1977;268(5618):358-360.
33. Jobe SM, Wilson KM, Leo L, et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood. 2008;111(3): 1257-1265.
34. Li J, Xia Y, Bertino AM, Coburn JP, Kuter DJ. The mechanism of apoptosis in human platelets during storage. Transfusion. 2000; 40(11):1320-1329.
35. Wolf BB, Goldstein JC, Stennicke HR, et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood. 1999;94(5): 1683-1692.
36. Bergmeier W, Burger PC, Piffath CL, et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood. 2003; 102(12):4229-4235.
37. Bertino AM, Qi XQ, Li J, Xia Y, Kuter DJ. Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion. 2003; 43(7):857-866.
38. Brown SB, Clarke MC, Magowan L, Sanderson H, Savill J. Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis. A caspase-independent cell clearance program. J Biol Chem. 2000;275(8): 5987-5996.
39. Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion. 2003;43(4):526-535.
40. Plenchette S, Moutet M, Benguella M, et al. Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. Leukemia. 2001;15(10):1572-1581
41. Lindsten T, Ross AJ, King A, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell. 2000;6(6):1389-1399.
42. Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science. 1995;270(5233):96-99.
43. Takeuchi O, Fisher J, Suh H, Harada H, Malynn BA, Korsmeyer SJ. Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease. Proc Natl Acad Sci USA. 2005;102(32):11272-11277.
44. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109(4):1503-1506.
45. de Graaf CA, Kauppi M, Baldwin T, et al. Regulation of hematopoietic stem cells by their mature progeny. Proc Natl Acad Sci USA. 2010;107(50):21689-21694.
46. Cookson P, Sutherland J, Turner C, et al. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. Transfus Med. 2010;20(6):392-402.
47. Dowling MR, Josefsson EC, Henley KJ, Hodgkin PD, Kile BT. Platelet senescence is regulated by an internal timer, not damage inflicted by hits. Blood. 2010;116(10): 1776-1778.
48. Mason KD, Lin A, Robb L, et al. Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. Proc Natl Acad Sci USA. 2013;110(7):2599-2604.
49. Liebman HA. Thrombocytopenia in cancer patients. Thromb Res. 2014;133(Suppl 2): S63-S69.
50. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005;11(5): 507-514.
51. Schoenwaelder SM, Darbousset R, Cranmer SL, et al. 14-3-3ζ regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function. Nat Commun. 2016;7:12862.
52. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood. 1993;82(6):1749-1757.
53. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005; 128(3):275-290.
54. Kramer PA, Ravi S, Chacko B, Johnson MS, Darley-Usmar VM. A review of the mitochondrial and glycolytic metabolism in human platelets and leukocytes: implications for their use as bioenergetic biomarkers. Redox Biol. 2014;2:206-210.
55. Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost. 2013;11(1):2-16.
56. Jackson SP, Schoenwaelder SM. Procoagulant platelets: are they necrotic? Blood. 2010; 116(12):2011-2018.
57. Kraemer BF, Campbell RA, Schwertz H, et al. Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. Blood. 2012;120(25):5014-5020.
58. Grozovsky R, Begonja AJ, Liu K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med. 2015;21(1):47-54.
59. Chen W, Liang X, Syed AK, et al. Inhibiting GPIba shedding preserves post-transfusion recovery and hemostatic function of platelets after prolonged storage. Arterioscler Thromb Vasc Biol. 2016;36(9):1821-1828.
60. Quach ME, Chen W, Li R. Mechanisms of platelet clearance and translation to improve platelet storage. Blood. 2018;131(14): 1512-1521.
61. Au AE, Josefsson EC. Regulation of platelet membrane protein shedding in health and disease. Platelets. 2017;28(4):342-353.
62. Cohen Z, Wilson J, Ritter L, McDonagh P. Caspase inhibition decreases both platelet phosphatidylserine exposure and aggregation: caspase inhibition of platelets. Thromb Res. 2004;113(6):387-393.